RTTNews | Nov 29, 2021 08:40AM EST

08:39 Monday, November 29, 2021 (RTTNews.com) - Athenex, Inc. (ATNX) said its Marketing Authorization Application for oral Paclitaxel for the treatment of advanced breast cancer has been validated by the United Kingdom's Medicines and Healthcare products Regulatory Agency for review. A single pivotal phase III study of oral Paclitaxel was the basis of the Marketing Authorization Application.

The company noted that the application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided.

Shares of Athenex were up 4% in pre-market trade on Monday.

Read the original article on RTTNews ( https://www.rttnews.com/3245344/athenex-announces-maa-validation-of-oral-paclitaxel-for-review-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved